IU Faculty-Founded Company Awarded $2 Million Grant for Anticancer Treatment
August 09, 2024
August 09, 2024
BLOOMINGTON, Indiana, Aug. 9 -- Indiana University issued the following news release:
NERx Biosciences, a pre-clinical stage biotechnology company, was awarded a $2 million grant from the National Institutes of Health's National Cancer Institute to further develop small molecule inhibitors that target the DNA Damage Response pathway for difficult-to-treat cancers, such as lung and ovarian cancer.
Cisplatin, the most prescribed cancer therapeutic, is known to cause . . .
NERx Biosciences, a pre-clinical stage biotechnology company, was awarded a $2 million grant from the National Institutes of Health's National Cancer Institute to further develop small molecule inhibitors that target the DNA Damage Response pathway for difficult-to-treat cancers, such as lung and ovarian cancer.
Cisplatin, the most prescribed cancer therapeutic, is known to cause . . .